Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q2 2022 Earnings Conference Call August 11, 2022 8:00 AM ET

Company Participants

Stephanie Ascher - Stern, Investor Relations

Bryan Stuart - President & Chief Executive Officer

Judy Dunn - President, Research & Development

Esther Rajavelu - Chief Financial Officer

Paul Bruno - Executive Director, Corporate Development

Conference Call Participants

Judah Frommer - Credit Suisse

Ted Tenthoff - Piper Sandler

Dae Gon Ha - Stifel

Matt Biegler - Oppenheimer

Joseph Schwartz - SVB

Yatin Suneja - Guggenheim

Operator

Good morning, and welcome to the Fulcrum Therapeutics Second Quarter 2022 Conference Call. Currently all participants are in a listen-only mode. There will be a question-and-answer session at the end of this call. Please note today's conference is being recorded.

I would now like to turn the call over to Stephanie Ascher from Stern Investor Relations. Please proceed.

Stephanie Ascher

Thank you, Rocco. Good morning, and welcome to the Fulcrum Therapeutics conference call. Please be reminded that remarks made during this call may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These may include statements about our future expectations and plans, clinical development timelines, and financial projections.

While these forward-looking statements represent our views as of today, they should not be relied upon as representing our views in the future. We may update these statements in the future, but we are not taking on an obligation to do so. Please refer to our most recent filings with the Securities and Exchange Commission for a discussion of certain risks and uncertainties associated with our business.

With me on today's call are Bryan Stuart, President and Chief Executive Officer; Judy Dunn, our President of Research & Development; and Esther Rajavelu, our Chief Financial Officer. In addition, Paul Bruno, our Executive Director of Corporate Development will be available for Q&A.

Let me quickly run through this morning's agenda. Bryan will begin the call with a corporate overview and key updates, Judy will review our clinical program. Esther will cover our financials and then Bryan will open the call for Q&A.

With that, it's my pleasure to turn the call over to Bryan.

Bryan Stuart

Thank you, Stephanie. Good morning, everyone and thank you for joining us today. At Fulcrum, our mission is to treat the root cause of rare genetic diseases. And in the second quarter of 2022, we have made significant progress in advancing two clinical-stage assets that support that mission. The first is our FSHD program, which is now in Phase III, positioning losmapimod to be the first-to-market therapy for an untreated patient population.